Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 103

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 103
---
 those securities in the form of units, as described
in the applicable prospectus supplement. Each series of rights will be issued under a separate rights agreement to be entered into between
us and a bank or trust company, as rights agent. The rights agent will act solely as our agent in connection with the certificates relating
to the rights of the series of certificates and will not assume any obligation or relationship of agency or trust for or with any holders
of rights certificates or beneficial owners of rights. The following description sets forth certain general terms and provisions of the
rights to which any prospectus supplement may relate. The particular terms of the rights to which any prospectus supplement may relate
and the extent, if any, to which the general provisions may apply to the rights so offered will be described in the applicable prospectus
supplement. To the extent that any particular terms of the rights, rights agreement or rights certificates described in a prospectus supplement
differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus
supplement. We encourage you to read the applicable rights agreement and rights certificate for additional information before you decide
whether to purchase any of our rights. We will provide in a prospectus supplement the following terms of the rights being issued:

| · | the date of determining the shareholders entitled to the rights distribution; |

| · | the aggregate number of Ordinary Shares represented by Depositary Shares or other securities purchasable 
 upon exercise of the rights;                                                                             |

| · | the exercise price; |

| · | the aggregate number of rights issued; |

| · | whether the rights are transferrable and the date, if any, on and after which the rights may be separately 
 transferred;                                                                                               |

| · | the date on which the right to exercise the rights will commence, and the date on which the right to exercise 
 the rights will expire;                                                                                       |

| · | the method by which holders of rights will be entitled to exercise; |

| · | the conditions to the completion of the offering, if any; |

| · | the withdrawal, termination and cancellation rights, if any; |

| · | whether there are any backstop or standby purchaser or purchasers and the terms of their commitment, if 
 any;                                                                                                    |

| · | whether shareholders are entitled to oversubscription rights, if any; |

| · | any applicable material United States federal income tax considerations and any applicable material United 
 Kingdom tax considerations; and